Company / EPS (Diluted)
BioMarin Pharmaceutical EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$1.80
FY2025
5-year range
-$0.13 / $2.21
FY2021-FY2025
Trend
-18.6%
vs FY2024
Sector context
#26 of 204
Health Care
What the data says
BioMarin Pharmaceutical's eps (diluted) of $1.80 is higher than 87% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-3.81 in FY2016 to $4.50 in FY2020.
Based on SEC 10-K filings.
1.80 in FY2025 with a 5-year CAGR of -16.7%. Top quartile in the Health Care sector.
Improved from $0.87 to $1.80 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +33.9%
- 5-Year CAGR
- -16.7%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 204This company $1.80 Sector average -$0.89
▼
+303.1% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 18.6% year-over-year.
- Ranks #26 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2020.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.80 | -18.6% |
| FY2024 | $2.21 | +154.0% |
| FY2023 | $0.87 | +16.0% |
| FY2022 | $0.75 | +676.9% |
| FY2021 | -$0.13 | -102.9% |
| FY2020 | $4.50 | +3561.5% |
| FY2019 | -$0.13 | +70.5% |
| FY2018 | -$0.44 | +34.3% |
| FY2017 | -$0.67 | +82.4% |
| FY2016 | -$3.81 | -256.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026